Effect of Spironolactone on Cardiac Remodeling After Acute Myocardial Infarction

Overview

Journal World J Emerg Med

Specialty Emergency Medicine

Date 2014 Sep 13

PMID 25215092

Citations 9

Authors

Chun-Tao Wu

Zhong-Hua Wang

Zhu-Qin Li

Lan-Feng Wang

Affiliations

Soon will be listed here.

Abstract

Background: Few studies have reported the effect of aldosterone receptor antagonist (ARA) on myocardial remodeling after acute myocardial infarction (AMI). This study was undertaken to investigate the preventive effect of ARA on myocardial remodeling after AMI.

Methods: A total of 616 patients who had been admitted into the CCU of the First Affiliated Hospital of Harbin Medical University from January 2008 to January 2010 were studied prospectively. Only 528 patients were observed completely, including 266 of the control group and 262 of the treatment group. There was no statistical difference in age, gender, medical history, admission situation, and treatment between the two groups (P>0.05). The preventive effects of spironolactone on cardiac remodeling, left ventricular function, renal function and blood levels of potassium were evaluated by echocardiography, serum potassium and serum creatinine at one-month and one-year follow-up.

Results: The echocardiography indicators such as LVESD, LVEDD, LVEF, LAD-ML and LAD-SI were significantly improved in the treatment group compared with the control group at one year (P<0.05). In the treatment group, LVESD, LVEDD, LVPWT, LVEF, LAD-ML and LAD-SI were more significantly improved at one year than one month (P<0.05, P=0.007 to LVEF), and in the control group LVEF was more significantly improved at one year than one month (P=0.0277). There were no significant differences in serum potassium and serum creatinine levels between the two groups.

Conclusion: On the basis of conventional treatment, the early combination of low-dose spironolactone (20 mg/d) could inhibit cardiac remodeling at late stage and prevent heart failure.

Citing Articles

The Gut Microbiota Mediates the Protective Effects of Spironolactone on Myocardial Infarction.

Li L, Sun J, Li Y, Zhu S, Duan S J Microbiol. 2024; 62(10):883-895.

PMID: 39225943 DOI: 10.1007/s12275-024-00164-7.

Aldosterone Blockade in Acute Myocardial Infarction: A Systematic Review and Meta-Analysis.

Chen Q, Zhao D, Sun J, Lu C Cardiovasc Ther. 2021; 2021:1710731.

PMID: 34786023 PMC: 8560277. DOI: 10.1155/2021/1710731.

Fabrication and Evaluation of Spironolactone-Loaded Nanostructured Lipid Carries for Cardiac Tissue Regeneration.

Falak M, Mehdikhani M, Varshosaz J, Hashemibeni B, Ebrahimian-Hosseinabadi M J Med Signals Sens. 2021; 10(4):260-265.

PMID: 33575198 PMC: 7866944. DOI: 10.4103/jmss.JMSS_46_19.

Hyperkalemia in ambulant postcardiac surgery patients during combined therapy with angiotensin-converting enzyme inhibitor, spironolactone, and diet rich in potassium: A report of two cases and review of literature.

Dixit A, Majumdar G, Tewari P Ann Card Anaesth. 2019; 22(2):162-168.

PMID: 30971598 PMC: 6489390. DOI: 10.4103/aca.ACA_65_18.

Efficacy of mineralocorticoid receptor antagonists in postmyocardial infarction patients with or without left ventricular dysfunction: A meta-analysis of randomized controlled trials.

Xu Y, Qiu Z, Yang R, Wu Y, Cheng X Medicine (Baltimore). 2018; 97(51):e13690.

PMID: 30572494 PMC: 6319977. DOI: 10.1097/MD.0000000000013690.

References

Furlan D, Sahnane N, Mazzoni M, Pastorino R, Carnevali I, Stefanoli M . Diagnostic utility of MS-MLPA in DNA methylation profiling of adenocarcinomas and neuroendocrine carcinomas of the colon-rectum. Virchows Arch. 2012; 462(1):47-56. DOI: 10.1007/s00428-012-1348-2. View

Milliez P, Deangelis N, Rucker-Martin C, Leenhardt A, Vicaut E, Robidel E . Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. Eur Heart J. 2005; 26(20):2193-9. DOI: 10.1093/eurheartj/ehi478. View

Nagata K . Mineralocorticoid antagonism and cardiac hypertrophy. Curr Hypertens Rep. 2008; 10(3):216-21. DOI: 10.1007/s11906-008-0041-y. View

Li W, Kong X, Zhang J, Yang J . Long-term intake of sesamin improves left ventricular remodelling in spontaneously hypertensive rats. Food Funct. 2012; 4(3):453-60. DOI: 10.1039/c2fo30220a. View

Danzmann L, Bodanese L, Kohler I, Torres M . Left atrioventricular remodeling in the assessment of the left ventricle diastolic function in patients with heart failure: a review of the currently studied echocardiographic variables. Cardiovasc Ultrasound. 2008; 6:56. PMC: 2615425. DOI: 10.1186/1476-7120-6-56. View

Jugdutt B . Matrix metalloproteinases as markers of adverse remodeling after myocardial infarction. J Card Fail. 2006; 12(1):73-6. DOI: 10.1016/j.cardfail.2005.10.001. View

Kayrak M, Bacaksiz A, Vatankulu M, Ayhan S, Ari H, Kaya Z . The effects of spironolactone on atrial remodeling in patients with preserved left ventricular function after an acute myocardial infarction: a randomized follow-up study. Coron Artery Dis. 2010; 21(8):477-85. DOI: 10.1097/MCA.0b013e32833fd243. View

Savoye C, Equine O, Tricot O, Nugue O, Segrestin B, Sautiere K . Left ventricular remodeling after anterior wall acute myocardial infarction in modern clinical practice (from the REmodelage VEntriculaire [REVE] study group). Am J Cardiol. 2006; 98(9):1144-9. DOI: 10.1016/j.amjcard.2006.06.011. View

Bousquet E, Zhao M, Ly A, Leroux Les Jardins G, Goldenberg B, Naud M . The aldosterone-mineralocorticoid receptor pathway exerts anti-inflammatory effects in endotoxin-induced uveitis. PLoS One. 2012; 7(11):e49036. PMC: 3494666. DOI: 10.1371/journal.pone.0049036. View

10.

Struthers A . The clinical implications of aldosterone escape in congestive heart failure. Eur J Heart Fail. 2004; 6(5):539-45. DOI: 10.1016/j.ejheart.2004.04.013. View

11.

Fiebeler A, Schmidt F, Muller D, Park J, Dechend R, Bieringer M . Mineralocorticoid receptor affects AP-1 and nuclear factor-kappab activation in angiotensin II-induced cardiac injury. Hypertension. 2001; 37(2 Pt 2):787-93. DOI: 10.1161/01.hyp.37.2.787. View

12.

Giallauria F, Galizia G, Lucci R, DAgostino M, Vitelli A, Maresca L . Favourable effects of exercise-based Cardiac Rehabilitation after acute myocardial infarction on left atrial remodeling. Int J Cardiol. 2008; 136(3):300-6. DOI: 10.1016/j.ijcard.2008.05.026. View

13.

Greco C, Castelli G, Crea F, Gavazzi A, Gensini G, Scherillo M . [New evidences on the use of aldosterone receptor antagonists in left ventricular dysfunction: from myocardial infarction to heart failure]. G Ital Cardiol (Rome). 2012; 13(12):809-16. DOI: 10.1714/1188.13164. View

14.

Vatankulu M, Bacaksiz A, Sonmez O, Alihanoglu Y, Koc F, Demir K . Does spironolactone have a dose-dependent effect on left ventricular remodeling in patients with preserved left ventricular function after an acute myocardial infarction?. Cardiovasc Ther. 2012; 31(4):224-9. DOI: 10.1111/1755-5922.12006. View

15.

Hayashi M, Tsutamoto T, Wada A, Tsutsui T, Ishii C, Ohno K . Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute.... Circulation. 2003; 107(20):2559-65. DOI: 10.1161/01.CIR.0000068340.96506.0F. View

16.

Kawazu T, Nishino T, Obata Y, Furusu A, Miyazaki M, Abe K . Production and degradation of extracellular matrix in reversible glomerular lesions in rat model of habu snake venom-induced glomerulonephritis. Med Mol Morphol. 2012; 45(4):190-8. DOI: 10.1007/s00795-011-0559-y. View

17.

Roscioni S, de Zeeuw D, Bakker S, Lambers Heerspink H . Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy. Nat Rev Nephrol. 2012; 8(12):691-9. DOI: 10.1038/nrneph.2012.217. View

18.

. Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J. 2000; 21(18):1502-13. DOI: 10.1053/euhj.2000.2305. View